Cellectis SA (CLLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cellectis SA (CLLS) has a cash flow conversion efficiency ratio of -0.348x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.28 Million) by net assets ($41.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Cellectis SA for the company's overall valuation and market capitalisation.
Cellectis SA - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Cellectis SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cellectis SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectis SA ranked by their cash flow conversion efficiency. Explore how high is Cellectis SA's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jati Tinggi Group Berhad
KLSE:0292
|
-0.081x |
|
Forsys Metals Corp.
TO:FSY
|
-0.019x |
|
Lhyfe SA
PA:LHYFE
|
-0.190x |
|
Kalray SA
PA:ALKAL
|
0.230x |
|
Han Chang Pape
KO:009460
|
0.054x |
|
NH All One REIT Co Ltd
KO:400760
|
N/A |
|
Charnic Capital Tbk PT
JK:NICK
|
-0.044x |
|
TCM Group
CO:TCM
|
0.087x |
Annual Cash Flow Conversion Efficiency for Cellectis SA (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cellectis SA from 2007 to 2025. View current stock price of Cellectis SA for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $75.90 Million | $-40.14 Million | -0.529x | -413.49% |
| 2024-12-31 | $131.03 Million | $22.10 Million | 0.169x | +157.73% |
| 2023-12-31 | $84.69 Million | $-24.75 Million | -0.292x | +57.92% |
| 2022-12-31 | $125.94 Million | $-87.44 Million | -0.694x | -57.03% |
| 2021-12-31 | $236.47 Million | $-104.56 Million | -0.442x | -70.15% |
| 2020-12-31 | $308.85 Million | $-80.26 Million | -0.260x | -33.61% |
| 2019-12-31 | $355.47 Million | $-69.14 Million | -0.195x | -28.54% |
| 2018-12-31 | $450.27 Million | $-68.14 Million | -0.151x | +17.32% |
| 2017-12-31 | $285.90 Million | $-52.33 Million | -0.183x | -61.34% |
| 2016-12-31 | $274.05 Million | $-31.09 Million | -0.113x | -1024.12% |
| 2015-12-31 | $288.22 Million | $3.54 Million | 0.012x | -98.25% |
| 2014-12-31 | $72.39 Million | $50.74 Million | 0.701x | +118.19% |
| 2013-12-31 | $6.65 Million | $-25.63 Million | -3.854x | -1105.67% |
| 2012-12-31 | $81.69 Million | $-26.11 Million | -0.320x | +10.29% |
| 2011-12-31 | $37.02 Million | $-13.19 Million | -0.356x | +15.35% |
| 2010-12-31 | $50.13 Million | $-21.10 Million | -0.421x | -337.25% |
| 2009-12-31 | $73.22 Million | $-7.05 Million | -0.096x | -350.06% |
| 2008-12-31 | $46.21 Million | $1.78 Million | 0.038x | +129.82% |
| 2007-12-31 | $43.54 Million | $-5.62 Million | -0.129x | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more